Przegla̜d Gastroenterologiczny最新文献

{"title":"Intrahepatic aneurysm in a branch of the right hepatic artery in a patient with vasculitis due to systemic lupus erythematosus.","authors":"Zoi Nitsa, Francesk Mulita, Maria Sotiropoulou, Andreas Panagakis, Markos Despotidis, Lysandros Karydakis, Dimitrios Schizas, Michail Vailas","doi":"10.5114/pg.2024.136247","DOIUrl":"https://doi.org/10.5114/pg.2024.136247","url":null,"abstract":"","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 2","pages":"214-216"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of Single-Pass Albumin Dialysis (SPAD), Prometheus, and Molecular Adsorbent Recycling System (MARS) liver haemodialysis vs. Standard Medical Therapy (SMT): meta-analysis and systematic review.","authors":"Eyad Gadour, Mohammed Abdullah Kaballo, Khalid Shrwani, Zeinab Hassan, Ahmed Kotb, Ahmed Aljuraysan, Bogdan Miuţescu, Nouf Sherwani, Waleed Mahallawi","doi":"10.5114/pg.2024.139297","DOIUrl":"https://doi.org/10.5114/pg.2024.139297","url":null,"abstract":"<p><strong>Introduction: </strong>Because not all liver dysfunction patients are suitable for transplantations and there is a shortage of grafts, liver support therapies have gained interest. In this regard, extracorporeal albumin dialysis devices such as single-pass albumin dialysis (SPAD), Prometheus, and molecular adsorbent recycling system (MARS) have been valuable in supplementing standard medical therapy (SMT). However, the efficacy and safety of these devices is often questioned.Aim: We performed a systematic review to summarize the efficacy and safety of MARS, SPAD, and Prometheus as supportive treatments for liver dysfunction.</p><p><strong>Material and methods: </strong>PubMed, Medline, Cochrane Library, Web of Science, and Google Scholar electronic databases were extensively searched for all randomized trials published in English. In addition, meta-analytic analyses were performed with Review Manager software, and Cochrane's risk of bias tool embedded in this software was used for bias assessment.</p><p><strong>Results: </strong>Twelve trials including a total of 653 patients were eligible for inclusion. Subgroup analyses of data from these trials revealed that MARS and Prometheus were associated with significant removal of bilirubin (MD = -5.14 mg/dl; 95% CI: -7.26 - -3.02; <i>p</i> < 0.00001 and MD = -8.11 mg/dl; 95% CI: -12.40 - -3.82; <i>p</i> = 0.0002, respectively) but not bile acids and ammonia when compared to SMT. Furthermore, MARS was as effective as Prometheus and SPAD in the reduction of bilirubin (MD = 2.98 mg/dl; 95% CI: -4.26 - 10.22; <i>p</i> = 0.42 and MD = 0.67 mg/dl; 95% CI: -2.22 - 3.56; <i>p</i> = 0.65), bile acids (MD = -17.06 µmol/l; 95% CI: -64.33 - 30.20; <i>p</i> = 0.48 and MD = 16.21 µmol/l; 95% CI: -17.26 - 49.68; <i>p</i> = 0.34), and ammonia (MD = 26 µmol/l; 95% CI: -12.44 - 64.44; <i>p</i> = 0.18). In addition, MARS had a considerable effect in improving hepatic encephalopathy (HE) (RR = 1.54; 95% CI: 1.15-2.05; <i>p</i> = 0.004). However, neither MARS nor Prometheus had a mortality benefit compared to SMTRR (0.86; 95% CI: 0.71-1.03; <i>p</i> = 0.11 and RR = 0.87; 95% CI: 0.66-1.14; <i>p</i> = 0.31, respectively).</p><p><strong>Conclusions: </strong>MARS, SPAD, and Prometheus, as liver support therapies, are equally effective in reducing albumin-bound and water-soluble substances. Moreover, MARS is associated with HE improvement. However, none of the therapies was associated with a significant reduction in mortality or adverse events.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 2","pages":"101-111"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of mental and psychological status with disease activity in patients with inflammatory bowel disease using SCL-90 R Questionnaire.","authors":"Ezzat Ali, Doaa Header, Khaled Abdel Aty, Nada Othman, Moamen Fawzy, Hussein El Amin, Mohamed Elnady","doi":"10.5114/pg.2024.139579","DOIUrl":"https://doi.org/10.5114/pg.2024.139579","url":null,"abstract":"<p><strong>Introduction: </strong>Inflammatory bowel disease (IBD) can affect mental health. There is no evidence that stress is a direct cause of the disease. Most IBD patients describe an emotional impact, mainly feelings of depression and anxiety. Many questionnaires are used to assess anxiety in those patients, including SCL-90.</p><p><strong>Aim: </strong>To investigate the correlation between mental and psychological status to disease activity in patients with inflammatory bowel disease using 90-Item Symptom Checklist (SCL-90 R) questionnaire.</p><p><strong>Material and methods: </strong>The study included 100 patients (50 Crohn's disease (CD) patients - 50 ulcerative colitis (UC) patients). Detailed history taking, systemic physical examination, laboratory investigations, colonoscopy, and the SCL-90-R symptom checklist - a self-report psychometric instrument (questionnaire) for each patient.</p><p><strong>Results: </strong>The mean age of Crohn's disease patients was 24.2 ±3.6 years. In ulcerative colitis the mean age was 28.5 ±7.3 years. No age or gender relation could be detected with the SCL-90 score in both groups. Our study showed a direct correlation of CD disease activity (CDAI) and endoscopic activity (SES) according to the SCL-90 R questionnaire. There was direct correlation of UC disease activity (SCCAI) and endoscopic activity (UCEIS) according to the SCL-90 R questionnaire.</p><p><strong>Conclusions: </strong>There is a direct correlation between disease activity and endoscopic activity in UC and CD according to the SCL-90 R questionnaire.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 2","pages":"165-174"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric polyps: a retrospective cohort analysis of 23,668 endoscopies indicates changing epidemiological and phenotypic characteristics.","authors":"Christina Kapizioni, Panagiotis Kourkoulis, Sofia Kartsoli, Georgios Koutoufaris, Panagiotis Giannelis, Aristotelis Mellos, Konstantia Milioni, George Michalopoulos, Spyridon Vrakas, Vasileios Xourgias","doi":"10.5114/pg.2024.136236","DOIUrl":"https://doi.org/10.5114/pg.2024.136236","url":null,"abstract":"<p><strong>Introduction: </strong>Growing adoption of endoscopic procedures in clinical practice has gradually increase the detection rate of gastric polypoid lesions.</p><p><strong>Aim: </strong>To identify the epidemiologic characteristics of gastric polyps as well as changes of these parameters during a 15-year period.</p><p><strong>Material and methods: </strong>We reviewed all the upper endoscopies archived in our database reporting a polypoid lesion from 2003 to 2018. Demographic data, indication for endoscopy, morphological characteristics of polyps, histology, and presence of <i>Helicobacter pylori</i> were collected. We compared the abovementioned data between 2 periods: 2003-2010 and 2010-2018.</p><p><strong>Results: </strong>A total of 989 (4.2%) patients from 23,668 reviewed were identified to harbour a polypoid lesion. Mean patient age was 63.2 years, with 58.8% being female. Most polyps (65.2%) were less than 5 mm in diameter and located in the fundus. Hyperplastic polyps (HPs) were the predominant type (28.6%) while fundic gland polyps (FGPs) were found in 24.1% of patients. Adenomas were the least common type (2.7%). Other pathology was identified in 43.3%. Comparison between the 2 periods revealed a rise of FGPs against HPs with a concomitant shift of location from antrum to fundus and an increase in the number of polyps per patient.</p><p><strong>Conclusions: </strong>FGPs and HPs were the most common polyps found in our cohort, with a change of their pattern during the 15 years. It is imperative to acknowledge the distinct characteristics of gastric polyps so as to properly assess the malignant potential that some of them, or their surrounding gastric mucosa, harbour.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 1","pages":"54-59"},"PeriodicalIF":1.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140870029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vonoprazan a novel potassium competitive acid blocker; another leap forward.","authors":"Maha Elsabaawy, Ahmed Shaban, Ahmed Ezz Al-Arab, Osama Elbahr, Ahmed Edrees, Sameh Afify","doi":"10.5114/pg.2024.139426","DOIUrl":"https://doi.org/10.5114/pg.2024.139426","url":null,"abstract":"<p><strong>Introduction: </strong>The eradication rate of <i>Helicobacter pylori</i> (<i>H. pylori</i>) has decreased due to antibiotics resistance and inadequate acid suppression. Vonoprazan is a novel potassium-competitive acid blocker (P-CAB), which has a rapid and sustained acid inhibitory effect and may be more effective than conventional proton pump inhibitors (PPIs) in <i>H. pylori</i> eradication.</p><p><strong>Aim: </strong>to study the efficacy and safety of vonoprazan as a component of first-line <i>H. pylori</i> eradication treatment compared with conventional PPI-based therapy.</p><p><strong>Material and methods: </strong>This randomised (one to one) non-blinded study was conducted on 400 consecutive proven <i>H. pylori</i> infected patients, of whom 200 received vonoprazan-based triple therapy, while 200 patients received PPI-based triple therapy for 14 days. The study outcomes were evaluated as eradication rate and adverse events in both patient groups.</p><p><strong>Results: </strong>The eradication rate was 86% in the vonoprazan group and 74.5% in the PPI group. The vonoprazan eradication rate was significantly higher than that of PPIs (<i>p</i> = 0.004). There was no significant difference regarding adverse events between both patient groups.</p><p><strong>Conclusions: </strong>Vonoprazan-based therapy was more effective than PPI-based therapy as a first-line <i>H. pylori</i> eradication treatment. Vonoprazan was generally safe and well tolerated.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 2","pages":"135-142"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role and therapeutic effectiveness of <i>Plantago ovata</i> seed husk (psyllium husk) in the prevention and non-pharmacological treatment of gastrointestinal diseases. Part 1. Clinical use of psyllium husk in the treatment of irritable bowel syndrome, ulcerative colitis, and colorectal cancer.","authors":"Justyna Przybyszewska, Andrzej Kuźmiński, Michał Przybyszewski, Cezary Popławski","doi":"10.5114/pg.2024.139209","DOIUrl":"https://doi.org/10.5114/pg.2024.139209","url":null,"abstract":"<p><p><i>Plantago ovata</i> is a common medicinal plant widely cultivated in tropical regions of the world. The outer seed coat of <i>P. ovata</i>, obtained by cleaning the seeds, contains soluble and insoluble fibre in a ratio of 7:3, making products containing <i>P. ovata</i> husk an ideal source of health-beneficial fibre. The results of clinical trials demonstrate the therapeutic efficacy of psyllium husk for various gastrointestinal disorders. It has also been documented that psyllium ingestion exhibits antioxidant, immunomodulatory, antiproliferative, anticancer, and antiviral effects. Such pleiotropic effects of <i>P. ovata</i> husk are related to the presence in its composition of arabinoxylan, which forms a gel in an aqueous environment, as well as bioactive compounds and their metabolites. This article presents the evidence available in the literature on the therapeutic potential and possible mechanisms of action of psyllium in the treatment of irritable bowel syndrome and ulcerative colitis, and prevention of colorectal cancer.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 2","pages":"121-126"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Forgettable in the care of liver cirrhosis: the unseen culprits of progression from bad to worse.","authors":"Maha Elsabaawy, Omkosoum Alhaddad","doi":"10.5114/pg.2024.136361","DOIUrl":"https://doi.org/10.5114/pg.2024.136361","url":null,"abstract":"<p><p>Patients with liver cirrhosis constitute a critically ill and unique population, and their stability relies on a well-coordinated multidisciplinary team with a carefully structured plan. Overlooking any aspect of this plan can expedite disease progression, leading to severe complications. The lack of disease-specific nutritional guidance, the prevalent sedentary lifestyle among patients, and insufficient screening for hepatocellular carcinoma, oesophageal varices, sarcopaenia, minimal hepatic encephalopathy, and diabetes mellitus, along with fibrosis progression and cirrhosis decompensation, can add further complexities. Additionally, devaluing the impact of obesity in triggering liver cirrhosis can be disadvantageous. Prolonged and inappropriate use of proton pump inhibitors also poses a significant challenge with a wide range of complications. These often-unheeded aspects in the care of liver cirrhosis patients represents the unseen culprits of progression from bad to worse and warrant serious consideration.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 1","pages":"6-17"},"PeriodicalIF":1.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140865156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of oxidative stress, metabolic disorders in colorectal cancer patients.","authors":"Konrad Zaręba, Justyna Dorf, Kerianne Cummings, Seena Tabibi, Mateusz Maciejczyk, Bogusław Kędra","doi":"10.5114/pg.2024.139995","DOIUrl":"https://doi.org/10.5114/pg.2024.139995","url":null,"abstract":"<p><strong>Introduction: </strong>Colorectal cancer have been one of the most common malignant neoplasm in the world. In most patients with this cancer, we can observe both redox homeostasis and nutritional disorders.</p><p><strong>Aim: </strong>To assess the occurrence of oxidative stress in patients with colorectal cancer and its severity depending on the nutritional status of patients.</p><p><strong>Material and methods: </strong>The study group consisted of 50 patients with colorectal cancer. In the control group, samples were obtained from 40 healthy subjects. Basal metabolic index and nutrition risk screening (NRS) 2002 scale was completed. The total antioxidant capacity (TAC), total oxidant status (TOS), malondialdehyde (MDA) were determined yielding the oxidative stress index (OSI) determined by the TOS/TAC ratio and TAC/MDA ratio.</p><p><strong>Results: </strong>There were statistically significant differences (<i>p</i> < 0.05) in the levels of not only TAC, TOS, OSI, but also MDA and TAC/MDA. In healthy patients, the TAC and TAC/MDA level was significantly higher (<i>p</i> < 0.05) compared to the cancer patients, while the TOS, OSI and MDA level was significantly lower (<i>p</i> < 0.05). In patients with BMI < 24.9 kg/m², the level of TAC was significantly higher and the level of TOS was significantly lower (<i>p</i> < 0.05) compared to patients with BMI > 24.9 kg/m². In patients with features of malnutrition according to the NRS 2002 scale, TOS and OSI were statistically significantly higher (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>Neoplastic disease, such as colorectal cancer, precipitates an increase in oxidative stress. Concurrently, the nutritional status of patients, especially malnutrition, further intensifies this process.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 2","pages":"206-213"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Clostridioides difficile</i> infection: a changing treatment paradigm.","authors":"Yousif Al Naser, Marriam AlGashami, Layth Aljashaami","doi":"10.5114/pg.2024.136237","DOIUrl":"https://doi.org/10.5114/pg.2024.136237","url":null,"abstract":"<p><p><i>Clostridioides difficile</i> infection (CDI) poses a persistent challenge in healthcare, with substantial morbidity and mortality implications. This comprehensive review explores current CDI management, emphasising guidelines from IDSA, SHEA, and ESCMID. Additionally, this study spotlights recent drug developments that have the potential to reshape CDI treatment paradigms. Within the current treatment landscape, fidaxomicin, vancomycin, bezlotoxumab, and faecal microbiota transplantation offer varied options, each with its unique strengths and limitations. Fidaxomicin, effective yet resource-constrained, presents a dilemma, with vancomycin emerging as a pragmatic alternative. Bezlotoxumab, though augmenting antibiotics, grapples with cost and safety concerns. Meanwhile, faecal microbiota transplantation, highly efficacious, confronts evolving safety considerations. The horizon of CDI treatment also features promising therapies such as SER-109 and Rebyota, epitomising the evolving paradigm. As CDI management advances, the critical role of standardised microbiome restoration therapies becomes evident, ensuring long-term safety and diversifying treatment strategies.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 1","pages":"1-5"},"PeriodicalIF":1.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140863772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional gastrointestinal disorders in Jordanian infants: a pilot study.","authors":"Yazan O Al Zu'bi, Eyad Altamimi, Ahmed H Al Sharie, Dawood Yusef, Wasim Khasawneh","doi":"10.5114/pg.2023.124757","DOIUrl":"10.5114/pg.2023.124757","url":null,"abstract":"<p><strong>Introduction: </strong>Functional gastrointestinal disorders (FGIDs) encompass a wide spectrum of disorders that may be diagnosed using the Rome criteria.</p><p><strong>Aim: </strong>To identify the prevalence and risk factors for the development of FGIDs in Jordanian infants.</p><p><strong>Material and methods: </strong>We conducted a cross-sectional study to investigate the prevalence of FGIDs among infants and characterise any possible risk factors. Between 1 January 2020, and 30 December 2020, patients who presented to the paediatric follow-up clinic at King Abdullah University Hospital were recruited. Parents were interviewed and asked to complete an Arabic version of the Rome IV diagnostic questionnaire for pediatric gastrointestinal disorders for neonates and toddlers. Data regarding the parents' gastrointestinal symptoms and children's medical history were collected. Children's electronic medical files were also reviewed.</p><p><strong>Results: </strong>The study included 127 children, 78 (61%) were males. The median age was 40 days. According to the Rome IV criteria eighty-two (64%) of the infants fit the diagnosis for at least one disorder. The most prevalent disorder was functional constipation (<i>n</i> = 78, 95%) followed by infant dyschezia (<i>n</i> = 11, 13%). Compared to infants who did not meet the diagnostic criteria, herb intake and circumcision rates were significantly higher among those who did. Univariate analyses revealed that Infants with FGIDs were more likely to ingest herbs.</p><p><strong>Conclusions: </strong>FGIDs were common among young infants. Functional constipation was the most commonly diagnosed FGID. Infants with with FGIDs were more likely to intake herbs to ease the symtpoms.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"1 1","pages":"67-73"},"PeriodicalIF":1.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70474818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}